Table 1.
Phenotypic and Molecular Characterization and Resistance Profile of the K. pneumonia.
| Beta-lactams | Fluoro chinolone |
Amino glycoside |
Colis tine |
Fosfo mycin |
Sulfo namide |
|||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mount/Year | Source | MLST | wzi | K-locus | O-locus | CZA | AMC | TZP | FEP | CAZ | C/T | MEM | IMI | AZT | MEV | FDC | CIP | TOB | AK | CN | CS | FOS | SXT | |
| S≤8 | S≤8 | S≤8 | S≤1 | S≤1 | S≤2 | S≤2 | S≤2 | S≤1 | S≤8 | S≤2 | S≤0,25 | S≤2 | S≤8 | S≤2 | S≤2 | S≤32 | S≤2 | |||||||
| R>8 | R>8 | R>8 | R>4 | R>4 | R>2 | R>2 | R>4 | R>4 | R>8 | R>2 | R>0,5 | R>2 | R>8 | R>2 | R>2 | R>32 | R>4 | |||||||
| 1CT | 06/20 | ST101 | 137 | K17 | O1/O2v1 | 16 | 32 | >64 | 32 | >32 | >256 | 1 | ≤0,25 | 32 | 0,5 | 1 | >2 | 16 | 32 | 16 | ≤0,25 | 16 | 2 | |
| 2CT | 06/20 | ST101 | 137 | K17 | O1/O2v1 | 16 | >32 | 64 | 16 | >32 | >256 | 16 | 16 | >1024 | 2 | 0,5 | 2 | 8 | 32 | 8 | ≤0,25 | 64 | 0,75 | |
| 3CT | 05/20 | ST101 | 137 | K17 | O1/O2v1 | 16 | 32 | >64 | 32 | >32 | >256 | 1 | ≤0,25 | >1024 | 0,5 | 0,5 | >2 | 16 | 32 | 16 | ≤0,25 | 128 | 3 | |
| 4CT | 08/21 | ST101 | 137 | K17 | O1/O2v1 | 16 | 32 | >64 | 32 | >32 | 32 | 16 | 16 | 1024 | 64 | 0,064 | >2 | 16 | >256 | 16 | ≤0,25 | 128 | 356 | |
| 5CT | 10/21 | ST101 | 137 | K17 | O1/O2v1 | 16 | 16 | 16 | 32 | >32 | 32 | 2 | ≤0,25 | 6 | 0,25 | 0,5 | >2 | 16 | 4 | 16 | 16 | 128 | ≤2 | |
| 1CZ | 04/20 | ST307 | 173 | K102 | O1/O2v2 | 16 | >32 | 32 | 32 | 16 | 8 | 16 | 8 | 8 | 0,06 | 0,064 | 2 | 8 | 4 | 8 | 16 | 128 | 16 | |
| 2CZ | 05/20 | ST512 | 154 | K107 | O1/O2v2 | 16 | >32 | 32 | 16 | 16 | 8 | >32 | 16 | 8 | 2 | 0,25 | 2 | 8 | 16 | ≤2 | 8 | 32 | 16 | |
| 3CZ | 06/20 | ST512 | 154 | K107 | O1/O2v2 | 16 | >32 | 32 | >32 | 16 | 8 | 16 | 16 | 8 | 0,25 | 0,125 | 2 | 8 | 32 | ≤2 | 8 | 32 | 16 | |
| 4CZ | 06/20 | ST307 | 173 | K102 | O1/O2v2 | 16 | >32 | 32 | 16 | 16 | 8 | >32 | 16 | 8 | 0,5 | 0,006 | 2 | ≤2 | 4 | ≤2 | 1 | ≤16 | 16 | |
| 5CZ | 08/20 | ST512 | 154 | K107 | O1/O2v2 | 32 | >32 | 64 | 32 | 32 | 32 | 4 | 0,5 | 8 | 1 | 1 | 4 | 8 | 16 | 8 | ≤0,25 | ≤16 | 16 | |
| 6CZ | 08/20 | ST512 | 154 | K107 | O1/O2v2 | 16 | >32 | 32 | 16 | 16 | 8 | >32 | 16 | 8 | 1 | 0,125 | 2 | 8 | 16 | ≤2 | 16 | ≤16 | 8 | |
| 7CZ | 09/20 | ST512 | 154 | K107 | O1/O2v2 | 16 | >32 | 32 | 16 | 16 | 8 | >32 | 16 | 8 | 1 | 0,125 | 2 | 8 | 16 | ≤2 | 8 | 128 | 8 | |
| 8CZ | 08/20 | ST512 | 154 | K107 | O1/O2v2 | 32 | >32 | 32 | 16 | 32 | 8 | >32 | 16 | 8 | 0,5 | 0,25 | 2 | 8 | 32 | ≤2 | 1 | ≤16 | 512 | |
| 9CZ | 09/20 | ST512 | 154 | K107 | O1/O2v2 | 32 | >32 | 32 | 32 | 32 | 8 | 16 | 32 | 8 | 0,5 | 0,25 | 2 | 8 | 32 | 8 | 16 | ≤16 | 512 | |
| 10CZ | 12/20 | ST101 | 137 | K17 | O1/O2v1 | 32 | >32 | 64 | >32 | 32 | 32 | 16 | 8 | 32 | 0,06 | 1 | 4 | ≥16 | 32 | 8 | ≤0,25 | 4 | ≤1 | |
| 12CZ | 02/21 | ST307 | 173 | K102 | O1/O2v2 | 32 | >32 | >64 | >32 | 32 | 64 | 32 | >32 | 64 | 0,25 | 0,012 | 4 | ≥16 | 16 | 16 | 4 | 64 | 16 | |
Antibiotic tested: CZA, ceftazidime/avibactam; AMC, amoxicillin/clavulanate; TZP, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; C/T, ceftazolane/tazobactam; MEM- meropenem; IMI, imipenem; AZT, aztreonam; MEV- meropenem/vaporbactam ; FDC, cefiderocol; CIP, ciprofloxacin; TOB, tobramycin; AK, amikacin; CN, gentamycin; CS, colistin; FOS, fosfomycin; SXT,trimethoprim/sulfamethoxazole.
⬤ Bronchoalveolar lavage.
⬤ Rectal swab.
⬤ Blood culture.
⬤ troath swab.
⬤ Burn swab.